Frankly this year I have no idea what ASCO will bring. There have been many years when biotech's in general got a boost out of what was presented at ASCO. Their have been others where ASCO was called a fiASCO, companies we though would flourish after ASCO floundered, and generally biotech's were down.
I don't believe that ASCO will harm us at all this year, we're so low I just don't think we'll go much lower with a decision from the UK due any day. Could it spur our price, sure, anything is possible. Most attendees are Drs. in the industry, not necessarily big investors, but some investors no doubt do attend.
I don't know who'll be in our booth, or just how much they can say, but perhaps someone will fill us in before it's over. I cannot say I've kept up with what other companies I'm not invested in may be presenting. I'm sure we'll hear of some highlights of the conference. The question is whether ASCO sends biotech's in general up, or down as we head into Summer and what generally are considered the Summer Doldrums'.
I don't believe we'll be in the Summer Doldrums' as we'll have news coming from the UK, and I believe after that the company will be announcing much more over time. Of course that's based on positive news from the UK.
I'm frankly in the process of selling roughly $2.4 million worth of property in Tahoe, but purchasing somewhat more than that on California's Northern Coast, and in New York. If possible I'd like to avoid new mortgages and I'm hoping that NWBO plays a part in making that happen. If not, the mortgages won't represent over 20% of the cost of the property, but my only reason for wanting mortgages is the simplicity of having the taxes and insurance impounded.
Gary
News 
Market Data 
Discover 
AI
